Digital Biomarkers Market By Type (Wearable, Mobile Application, Others), By Application (Cardiovascular Disease, Diabetes, Neurological Disorders, Respiratory Disease, Others), By Clinical Practice (Monitoring, Diagnostic, Prognostic), By End User (Healthcare Providers, Healthcare Consumers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Digital Biomarkers Market

Digital biomarkers refer to digital devices or technologies which can encompass a wide range of data, including physiological parameters (heart rate, blood pressure, and sleep patterns), activity levels, cognitive performance, speech patterns, gait analysis, social media behavior, and more. These biomarkers are often collected in real-time or near real-time, allowing for continuous monitoring and analysis. Digital biomarkers hold promise in various areas, including chronic disease management, mental health monitoring, precision medicine, clinical trials, wellness and preventive care, and patient engagement.

Key factors driving the growth of the digital biomarkers market include rise in prevalence of chronic diseases, high presence of market players, and surge in number of geriatric populations. Moreover, rise in number of product approvals and product launches for digital biomarker is anticipated to boost the growth of the market. For instance, in September 2022, Feel Therapeutics Inc., a leading company of developing digital biomarkers and therapeutics, announced the launch of its digital precision medicine platform. Through its proprietary platform, Feel therapeutics can collect clinically valuable data points passively and on a 24/7 basis to generate real-world evidence (RWE) and discover novel digital biomarkers and endpoints.

In addition, High presence of market players and rise in number of strategic partnerships and business expansions associated to digital biomarkers is anticipated to boost the growth of the market. For instance, in February 2022, Koneksa, the leader in designing and validating digital biomarkers to accelerate drug development, announced the completion of a $45 million Series C financing round, led by AyurMaya, an affiliated fund of matrix capital management. This financing accelerates expansion of digital biomarker platform.

Moreover, high presence of market players who manufacture technologically advanced digital biomarkers is anticipated to boost the growth of the market. For instance, ActiGraph LLC, chugai-pharm, Verily Life Sciences, Alivecor, koneksahealth, Altoida, Amgen, Feel Therapeutics, Brainomix, Sonde Health, Inc., Empatica are major market players who manufacture technologically advanced digital biomarkers.

The digital biomarkers market is segmented on the basis of type, application, end user and region. By type the market is divided into wearable, mobile application, software, and others (sensor, card, and implantable). By application, the market is classified into cardiovascular disease, sleep & movement disease, neurological disorders, and others. (respiratory diseases, diabetes, psychiatric and musculoskeletal disorders). By end user, the market is divided into healthcare companies, hospitals, and others (payers and patients). Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The key players profiled in the study include ActiGraph LLC, Verily Life Sciences, Alivecor, koneksahealth, Amgen, Brainomix, Feel Therapeutics, Sonde Health, Inc., Empatica, Clario. The players in the market have been actively engaged in the adoption various strategies such as acquisition, product launch and expansion to remain competitive and gain advantage over the competitors in the market. For instance, in September 2022, Feel Therapeutics Inc., a leading company of developing digital biomarkers and therapeutics, announced the launch of its digital precision medicine platform. Through its proprietary platform, Feel can collect clinically valuable data points passively and on a 24/7 basis to generate real-world evidence (RWE) and discover novel digital biomarkers and endpoints.

In addition, rise in the number of product launch and product approvals for digital biomarkers. For instance, in March 2023, brainTale, a biotechnology research company, announces the new release of its CE-marked version of the brainTale-care digital biomarker platform under European regulation. BrainTale-care is a clinically evaluated software medical device available in Software as a Service (SaaS) mode for physician. It provides reliable, reproducible, and quantitative measurement of the brain.

Key Market Insights

By type, wearable segment was the highest revenue contributor to the market and is estimated to reach $9,075.6 million by 2032, with a CAGR of 21.3%.

By application, the cardiovascular disease segment dominated the global market. However, the diabetes segment is expected to be the fastest-growing segment with a CAGR of 22.3% during the forecast period.

By clinical practice, the monitoring segment dominated the global market. However, the diagnostics segment is expected to be the fastest-growing segment with a CAGR of 21.8% during the forecast period.

By end user, the healthcare consumers segment dominated the global market. However, the healthcare providers segment is expected to be the fastest-growing segment with a CAGR of 22.0% during the forecast period.

Based on region, North America garnered the largest revenue share in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 22.3% during the forecast period

Overview

The digital biomarkers market was valued for $2,125.95 million in 2022 and is estimated to reach $14,678.40 million by 2032, exhibiting a CAGR of 21.3% from 2023 to 2032.

Digital biomarkers are characterized as measurable physiological and behavioral data that are obtained and assessed using digital devices such as portable, wearable, implantable, or ingestible ones. The information gathered is often used to forecast, affect, or explain outcomes connected to health. Digital biomarkers offer another chance to gather factual data that has therapeutic significance. This innovative open-access multidisciplinary approach unites informatics, engineering, biomedicine, regulatory science, and computer science.

The digital biomarkers market growth is driven by high presence of market players who manufacture digital biomarkers and increase in prevalence of chronic diseases such as cardiovascular diseases, respiratory diseases, psychiatric diseases, neurological diseases, and others. Digital biomarkers are used to monitor a wide range of diseases and health conditions. Digital biomarkers aim to monitor heart rate, heart rate variability, blood pressure, and other related parameters to assess the risk of cardiovascular diseases such as hypertension, arrhythmias, and heart failure. These biomarkers can be utilized to assess and monitor mental health conditions such as depression, anxiety, and bipolar disorder by analyzing patterns in sleep, activity levels, social interactions, and speech characteristics.

Moreover, digital biomarkers can aid in the monitoring and management of neurological conditions like Parkinson's disease, Alzheimer's disease, multiple sclerosis, and epilepsy. These biomarkers can include gait analysis, tremor frequency, cognitive performance, and sleep disturbances. Digital biomarkers can help track and analyze pain levels, activity patterns, sleep quality, and mood fluctuations in patients with chronic pain conditions, assisting in personalized pain management approaches.

For instance, according to the British Heart Foundation, in 2022, around 1,139,140 people were reported to have been suffering from heart and circulatory diseases in the UK. As per the same source, in 2022, around 650,681 male and 488,320 female population were suffering from heart and circulatory diseases in the UK. Thus, rise in number of chronic diseases is anticipated to drive the demand for digital biomarker and boost the growth of the market.

In addition, geriatric population is more susceptible to chronic diseases such as cardiovascular diseases, neurological disorders, respiratory diseases, and others. Thus, increase in the number of geriatric populations is expected to witness growth in prevalence of neurological diseases such as Alzheimer's dementia (AD). Therefore, this is expected to increase the demand for digital biomarkers and boost the growth of the market. According to World Health Organization, (WHO), population aged 60 years and over were expected to increase from 1 billion in 2020 to 1.4 billion in 2022 globally. By 2050, the global population of people aged 60 years and older is expected to increase by two-fold. The number of people aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.

Moreover, according to Alzheimer's Association, in 2022, an estimated 6.5 million Americans aged 65 and older were reported to have been living with Alzheimer's dementia (AD). This number is projected to grow to 13.8 million by 2060. On the other hand, data privacy and security concerns, and lack of awareness is anticipated to hamper the growth of the market. However, increase in demand for digital medical devices in the developed countries such as U.S., Canada, and Germany and growth opportunities in emerging markets are expected to create immense opportunities for the digital biomarkers market during the forecast period.

The digital biomarkers market is segmented on the basis of type, application, end user and region. By type the market is divided into wearable, mobile application, software, and others (sensor, card, and implantable). By application, the market is classified into cardiovascular disease, sleep & movement disease, neurological disorders, and others. (respiratory diseases, diabetes, psychiatric and musculoskeletal disorders). By clinical practice, the market is classified into monitoring, diagnostic and prognostic. By end user, the market is divided into healthcare companies, hospitals, and others (payers and patients)

Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Major key players that operate in the global digital biomarkers market are ActiGraph LLC, Verily Life Sciences, Alivecor, koneksahealth, Amgen, Brainomix, Feel Therapeutics, Sonde Health, Inc., Empatica, Clario. Key players operating in the market have adopted product approval, product launch, acquisition and agreement as their key strategies to expand their digital biomarkers market share.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the digital biomarkers market analysis from 2022 to 2032 to identify the prevailing digital biomarkers market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the digital biomarkers market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global digital biomarkers market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

● Product Benchmarking / Product specification and applications

○ Verily Life Sciences LL

Scope of Digital Biomarkers Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Low bargaining power of suppliers

3.3.2. Low threat of new entrants

3.3.3. Low threat of substitutes

3.3.4. Low intensity of rivalry

3.3.5. Low bargaining power of buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rise in prevalence of chronic diseases

3.4.1.2. Increase in number of geriatric populations

3.4.1.3. Benefits associated with digital biomarkers

3.4.2. Restraints

3.4.2.1. Data security issue

3.4.3. Opportunities

3.4.3.1. Rise in number of product approvals and products launches by market players.

3.4.3.2. High presence of market players

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market size and forecast

4.2. Wearable

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Mobile Application

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Others

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Cardiovascular Disease

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Diabetes

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Neurological Disorders

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

5.5. Respiratory Disease

5.5.1. Key market trends, growth factors and opportunities

5.5.2. Market size and forecast, by region

5.5.3. Market share analysis by country

5.6. Others

5.6.1. Key market trends, growth factors and opportunities

5.6.2. Market size and forecast, by region

5.6.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Monitoring

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Diagnostic

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Prognostic

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast

7.2. Healthcare Providers

7.2.1. Key market trends, growth factors and opportunities

7.2.2. Market size and forecast, by region

7.2.3. Market share analysis by country

7.3. Healthcare Consumers

7.3.1. Key market trends, growth factors and opportunities

7.3.2. Market size and forecast, by region

7.3.3. Market share analysis by country

7.4. Others

7.4.1. Key market trends, growth factors and opportunities

7.4.2. Market size and forecast, by region

7.4.3. Market share analysis by country

8.1. Overview

8.1.1. Market size and forecast By Region

8.2. North America

8.2.1. Key trends and opportunities

8.2.2. Market size and forecast, by Type

8.2.3. Market size and forecast, by Application

8.2.4. Market size and forecast, by Clinical Practice

8.2.5. Market size and forecast, by End User

8.2.6. Market size and forecast, by country

8.2.6.1. U.S.

8.2.6.1.1. Key market trends, growth factors and opportunities

8.2.6.1.2. Market size and forecast, by Type

8.2.6.1.3. Market size and forecast, by Application

8.2.6.1.4. Market size and forecast, by Clinical Practice

8.2.6.1.5. Market size and forecast, by End User

8.2.6.2. Canada

8.2.6.2.1. Key market trends, growth factors and opportunities

8.2.6.2.2. Market size and forecast, by Type

8.2.6.2.3. Market size and forecast, by Application

8.2.6.2.4. Market size and forecast, by Clinical Practice

8.2.6.2.5. Market size and forecast, by End User

8.2.6.3. Mexico

8.2.6.3.1. Key market trends, growth factors and opportunities

8.2.6.3.2. Market size and forecast, by Type

8.2.6.3.3. Market size and forecast, by Application

8.2.6.3.4. Market size and forecast, by Clinical Practice

8.2.6.3.5. Market size and forecast, by End User

8.3. Europe

8.3.1. Key trends and opportunities

8.3.2. Market size and forecast, by Type

8.3.3. Market size and forecast, by Application

8.3.4. Market size and forecast, by Clinical Practice

8.3.5. Market size and forecast, by End User

8.3.6. Market size and forecast, by country

8.3.6.1. Germany

8.3.6.1.1. Key market trends, growth factors and opportunities

8.3.6.1.2. Market size and forecast, by Type

8.3.6.1.3. Market size and forecast, by Application

8.3.6.1.4. Market size and forecast, by Clinical Practice

8.3.6.1.5. Market size and forecast, by End User

8.3.6.2. France

8.3.6.2.1. Key market trends, growth factors and opportunities

8.3.6.2.2. Market size and forecast, by Type

8.3.6.2.3. Market size and forecast, by Application

8.3.6.2.4. Market size and forecast, by Clinical Practice

8.3.6.2.5. Market size and forecast, by End User

8.3.6.3. UK

8.3.6.3.1. Key market trends, growth factors and opportunities

8.3.6.3.2. Market size and forecast, by Type

8.3.6.3.3. Market size and forecast, by Application

8.3.6.3.4. Market size and forecast, by Clinical Practice

8.3.6.3.5. Market size and forecast, by End User

8.3.6.4. Italy

8.3.6.4.1. Key market trends, growth factors and opportunities

8.3.6.4.2. Market size and forecast, by Type

8.3.6.4.3. Market size and forecast, by Application

8.3.6.4.4. Market size and forecast, by Clinical Practice

8.3.6.4.5. Market size and forecast, by End User

8.3.6.5. Spain

8.3.6.5.1. Key market trends, growth factors and opportunities

8.3.6.5.2. Market size and forecast, by Type

8.3.6.5.3. Market size and forecast, by Application

8.3.6.5.4. Market size and forecast, by Clinical Practice

8.3.6.5.5. Market size and forecast, by End User

8.3.6.6. Rest of Europe

8.3.6.6.1. Key market trends, growth factors and opportunities

8.3.6.6.2. Market size and forecast, by Type

8.3.6.6.3. Market size and forecast, by Application

8.3.6.6.4. Market size and forecast, by Clinical Practice

8.3.6.6.5. Market size and forecast, by End User

8.4. Asia-Pacific

8.4.1. Key trends and opportunities

8.4.2. Market size and forecast, by Type

8.4.3. Market size and forecast, by Application

8.4.4. Market size and forecast, by Clinical Practice

8.4.5. Market size and forecast, by End User

8.4.6. Market size and forecast, by country

8.4.6.1. Japan

8.4.6.1.1. Key market trends, growth factors and opportunities

8.4.6.1.2. Market size and forecast, by Type

8.4.6.1.3. Market size and forecast, by Application

8.4.6.1.4. Market size and forecast, by Clinical Practice

8.4.6.1.5. Market size and forecast, by End User

8.4.6.2. China

8.4.6.2.1. Key market trends, growth factors and opportunities

8.4.6.2.2. Market size and forecast, by Type

8.4.6.2.3. Market size and forecast, by Application

8.4.6.2.4. Market size and forecast, by Clinical Practice

8.4.6.2.5. Market size and forecast, by End User

8.4.6.3. India

8.4.6.3.1. Key market trends, growth factors and opportunities

8.4.6.3.2. Market size and forecast, by Type

8.4.6.3.3. Market size and forecast, by Application

8.4.6.3.4. Market size and forecast, by Clinical Practice

8.4.6.3.5. Market size and forecast, by End User

8.4.6.4. Australia

8.4.6.4.1. Key market trends, growth factors and opportunities

8.4.6.4.2. Market size and forecast, by Type

8.4.6.4.3. Market size and forecast, by Application

8.4.6.4.4. Market size and forecast, by Clinical Practice

8.4.6.4.5. Market size and forecast, by End User

8.4.6.5. South Korea

8.4.6.5.1. Key market trends, growth factors and opportunities

8.4.6.5.2. Market size and forecast, by Type

8.4.6.5.3. Market size and forecast, by Application

8.4.6.5.4. Market size and forecast, by Clinical Practice

8.4.6.5.5. Market size and forecast, by End User

8.4.6.6. Rest of Asia-Pacific

8.4.6.6.1. Key market trends, growth factors and opportunities

8.4.6.6.2. Market size and forecast, by Type

8.4.6.6.3. Market size and forecast, by Application

8.4.6.6.4. Market size and forecast, by Clinical Practice

8.4.6.6.5. Market size and forecast, by End User

8.5. LAMEA

8.5.1. Key trends and opportunities

8.5.2. Market size and forecast, by Type

8.5.3. Market size and forecast, by Application

8.5.4. Market size and forecast, by Clinical Practice

8.5.5. Market size and forecast, by End User

8.5.6. Market size and forecast, by country

8.5.6.1. Brazil

8.5.6.1.1. Key market trends, growth factors and opportunities

8.5.6.1.2. Market size and forecast, by Type

8.5.6.1.3. Market size and forecast, by Application

8.5.6.1.4. Market size and forecast, by Clinical Practice

8.5.6.1.5. Market size and forecast, by End User

8.5.6.2. South Africa,

8.5.6.2.1. Key market trends, growth factors and opportunities

8.5.6.2.2. Market size and forecast, by Type

8.5.6.2.3. Market size and forecast, by Application

8.5.6.2.4. Market size and forecast, by Clinical Practice

8.5.6.2.5. Market size and forecast, by End User

8.5.6.3. Saudi Arabia

8.5.6.3.1. Key market trends, growth factors and opportunities

8.5.6.3.2. Market size and forecast, by Type

8.5.6.3.3. Market size and forecast, by Application

8.5.6.3.4. Market size and forecast, by Clinical Practice

8.5.6.3.5. Market size and forecast, by End User

8.5.6.4. Rest of LAMEA

8.5.6.4.1. Key market trends, growth factors and opportunities

8.5.6.4.2. Market size and forecast, by Type

8.5.6.4.3. Market size and forecast, by Application

8.5.6.4.4. Market size and forecast, by Clinical Practice

8.5.6.4.5. Market size and forecast, by End User

9.1. Introduction

9.2. Top winning strategies

9.3. Product Mapping of Top 10 Player

9.4. Competitive Dashboard

9.5. Competitive Heatmap

9.6. Top player positioning, 2022

10.1. ActiGraph LLC

10.1.1. Company overview

10.1.2. Key Executives

10.1.3. Company snapshot

10.1.4. Operating business segments

10.1.5. Product portfolio

10.1.6. Key strategic moves and developments

10.2. Verily Life Sciences LLC

10.2.1. Company overview

10.2.2. Key Executives

10.2.3. Company snapshot

10.2.4. Operating business segments

10.2.5. Product portfolio

10.3. AliveCor

10.3.1. Company overview

10.3.2. Key Executives

10.3.3. Company snapshot

10.3.4. Operating business segments

10.3.5. Product portfolio

10.3.6. Key strategic moves and developments

10.4. Koneksahealth

10.4.1. Company overview

10.4.2. Key Executives

10.4.3. Company snapshot

10.4.4. Operating business segments

10.4.5. Product portfolio

10.4.6. Key strategic moves and developments

10.5. Amgen Inc.

10.5.1. Company overview

10.5.2. Key Executives

10.5.3. Company snapshot

10.5.4. Operating business segments

10.5.5. Product portfolio

10.5.6. Business performance

10.6. Empatica

10.6.1. Company overview

10.6.2. Key Executives

10.6.3. Company snapshot

10.6.4. Operating business segments

10.6.5. Product portfolio

10.6.6. Key strategic moves and developments

10.7. Sonde Health, Inc.

10.7.1. Company overview

10.7.2. Key Executives

10.7.3. Company snapshot

10.7.4. Operating business segments

10.7.5. Product portfolio

10.8. Clario

10.8.1. Company overview

10.8.2. Key Executives

10.8.3. Company snapshot

10.8.4. Operating business segments

10.8.5. Product portfolio

10.9. Feel Therapeutics

10.9.1. Company overview

10.9.2. Key Executives

10.9.3. Company snapshot

10.9.4. Operating business segments

10.9.5. Product portfolio

10.9.6. Key strategic moves and developments

10.10. Brainomix

10.10.1. Company overview

10.10.2. Key Executives

10.10.3. Company snapshot

10.10.4. Operating business segments

10.10.5. Product portfoli

LIST OF TABLES

TABLE 01. GLOBAL DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 02. DIGITAL BIOMARKERS MARKET FOR WEARABLE, BY REGION, 2022-2032 ($MILLION)

TABLE 03. DIGITAL BIOMARKERS MARKET FOR MOBILE APPLICATION, BY REGION, 2022-2032 ($MILLION)

TABLE 04. DIGITAL BIOMARKERS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 05. GLOBAL DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 06. DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2022-2032 ($MILLION)

TABLE 07. DIGITAL BIOMARKERS MARKET FOR DIABETES, BY REGION, 2022-2032 ($MILLION)

TABLE 08. DIGITAL BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022-2032 ($MILLION)

TABLE 09. DIGITAL BIOMARKERS MARKET FOR RESPIRATORY DISEASE, BY REGION, 2022-2032 ($MILLION)

TABLE 10. DIGITAL BIOMARKERS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 11. GLOBAL DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 12. DIGITAL BIOMARKERS MARKET FOR MONITORING, BY REGION, 2022-2032 ($MILLION)

TABLE 13. DIGITAL BIOMARKERS MARKET FOR DIAGNOSTIC, BY REGION, 2022-2032 ($MILLION)

TABLE 14. DIGITAL BIOMARKERS MARKET FOR PROGNOSTIC, BY REGION, 2022-2032 ($MILLION)

TABLE 15. GLOBAL DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 16. DIGITAL BIOMARKERS MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2022-2032 ($MILLION)

TABLE 17. DIGITAL BIOMARKERS MARKET FOR HEALTHCARE CONSUMERS, BY REGION, 2022-2032 ($MILLION)

TABLE 18. DIGITAL BIOMARKERS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 19. DIGITAL BIOMARKERS MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 20. NORTH AMERICA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 21. NORTH AMERICA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 22. NORTH AMERICA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 23. NORTH AMERICA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 24. NORTH AMERICA DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 25. U.S. DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 26. U.S. DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 27. U.S. DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 28. U.S. DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 29. CANADA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 30. CANADA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 31. CANADA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 32. CANADA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 33. MEXICO DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 34. MEXICO DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 35. MEXICO DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 36. MEXICO DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 37. EUROPE DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 38. EUROPE DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 39. EUROPE DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 40. EUROPE DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 41. EUROPE DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 42. GERMANY DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 43. GERMANY DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 44. GERMANY DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 45. GERMANY DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 46. FRANCE DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 47. FRANCE DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 48. FRANCE DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 49. FRANCE DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 50. UK DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 51. UK DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 52. UK DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 53. UK DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 54. ITALY DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 55. ITALY DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 56. ITALY DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 57. ITALY DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 58. SPAIN DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 59. SPAIN DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 60. SPAIN DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 61. SPAIN DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 62. REST OF EUROPE DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 63. REST OF EUROPE DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 64. REST OF EUROPE DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 65. REST OF EUROPE DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 66. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 67. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 68. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 69. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 70. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 71. JAPAN DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 72. JAPAN DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 73. JAPAN DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 74. JAPAN DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 75. CHINA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 76. CHINA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 77. CHINA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 78. CHINA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 79. INDIA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 80. INDIA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 81. INDIA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 82. INDIA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 83. AUSTRALIA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 84. AUSTRALIA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 85. AUSTRALIA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 86. AUSTRALIA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 87. SOUTH KOREA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 88. SOUTH KOREA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 89. SOUTH KOREA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 90. SOUTH KOREA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 91. REST OF ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 92. REST OF ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 93. REST OF ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 94. REST OF ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 95. LAMEA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 96. LAMEA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 97. LAMEA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 98. LAMEA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 99. LAMEA DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 100. BRAZIL DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 101. BRAZIL DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 102. BRAZIL DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 103. BRAZIL DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 104. SOUTH AFRICA, DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 105. SOUTH AFRICA, DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 106. SOUTH AFRICA, DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 107. SOUTH AFRICA, DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 108. SAUDI ARABIA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 109. SAUDI ARABIA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 110. SAUDI ARABIA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 111. SAUDI ARABIA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 112. REST OF LAMEA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 113. REST OF LAMEA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 114. REST OF LAMEA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)

TABLE 115. REST OF LAMEA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 116. ACTIGRAPH LLC: KEY EXECUTIVES

TABLE 117. ACTIGRAPH LLC: COMPANY SNAPSHOT

TABLE 118. ACTIGRAPH LLC: PRODUCT SEGMENTS

TABLE 119. ACTIGRAPH LLC: SERVICE SEGMENTS

TABLE 120. ACTIGRAPH LLC: PRODUCT PORTFOLIO

TABLE 121. ACTIGRAPH LLC: KEY STRATERGIES

TABLE 122. VERILY LIFE SCIENCES LLC: KEY EXECUTIVES

TABLE 123. VERILY LIFE SCIENCES LLC: COMPANY SNAPSHOT

TABLE 124. VERILY LIFE SCIENCES LLC: PRODUCT SEGMENTS

TABLE 125. VERILY LIFE SCIENCES LLC: PRODUCT PORTFOLIO

TABLE 126. ALIVECOR: KEY EXECUTIVES

TABLE 127. ALIVECOR: COMPANY SNAPSHOT

TABLE 128. ALIVECOR: PRODUCT SEGMENTS

TABLE 129. ALIVECOR: SERVICE SEGMENTS

TABLE 130. ALIVECOR: PRODUCT PORTFOLIO

TABLE 131. ALIVECOR: KEY STRATERGIES

TABLE 132. KONEKSAHEALTH: KEY EXECUTIVES

TABLE 133. KONEKSAHEALTH: COMPANY SNAPSHOT

TABLE 134. KONEKSAHEALTH: PRODUCT SEGMENTS

TABLE 135. KONEKSAHEALTH: PRODUCT PORTFOLIO

TABLE 136. KONEKSAHEALTH: KEY STRATERGIES

TABLE 137. AMGEN INC.: KEY EXECUTIVES

TABLE 138. AMGEN INC.: COMPANY SNAPSHOT

TABLE 139. AMGEN INC.: PRODUCT SEGMENTS

TABLE 140. AMGEN INC.: PRODUCT PORTFOLIO

TABLE 141. EMPATICA: KEY EXECUTIVES

TABLE 142. EMPATICA: COMPANY SNAPSHOT

TABLE 143. EMPATICA: PRODUCT SEGMENTS

TABLE 144. EMPATICA: PRODUCT PORTFOLIO

TABLE 145. EMPATICA: KEY STRATERGIES

TABLE 146. SONDE HEALTH, INC.: KEY EXECUTIVES

TABLE 147. SONDE HEALTH, INC.: COMPANY SNAPSHOT

TABLE 148. SONDE HEALTH, INC.: PRODUCT SEGMENTS

TABLE 149. SONDE HEALTH, INC.: PRODUCT PORTFOLIO

TABLE 150. CLARIO: KEY EXECUTIVES

TABLE 151. CLARIO: COMPANY SNAPSHOT

TABLE 152. CLARIO: PRODUCT SEGMENTS

TABLE 153. CLARIO: PRODUCT PORTFOLIO

TABLE 154. FEEL THERAPEUTICS: KEY EXECUTIVES

TABLE 155. FEEL THERAPEUTICS: COMPANY SNAPSHOT

TABLE 156. FEEL THERAPEUTICS: PRODUCT SEGMENTS

TABLE 157. FEEL THERAPEUTICS: PRODUCT PORTFOLIO

TABLE 158. FEEL THERAPEUTICS: KEY STRATERGIES

TABLE 159. BRAINOMIX: KEY EXECUTIVES

TABLE 160. BRAINOMIX: COMPANY SNAPSHOT

TABLE 161. BRAINOMIX: PRODUCT SEGMENTS

TABLE 162. BRAINOMIX: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. DIGITAL BIOMARKERS MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF DIGITAL BIOMARKERS MARKET, 2022-2032

FIGURE 03. DIGITAL BIOMARKERS MARKET,2022-2032

FIGURE 04. TOP INVESTMENT POCKETS IN DIGITAL BIOMARKERS MARKET (2023-2032)

FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS

FIGURE 06. LOW THREAT OF NEW ENTRANTS

FIGURE 07. LOW THREAT OF SUBSTITUTES

FIGURE 08. LOW INTENSITY OF RIVALRY

FIGURE 09. LOW BARGAINING POWER OF BUYERS

FIGURE 10. GLOBAL DIGITAL BIOMARKERS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 11. DIGITAL BIOMARKERS MARKET, BY TYPE, 2022(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR WEARABLE, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR MOBILE APPLICATION, BY COUNTRY 2022 AND 2032(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 15. DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY 2022 AND 2032(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR DIABETES, BY COUNTRY 2022 AND 2032(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR RESPIRATORY DISEASE, BY COUNTRY 2022 AND 2032(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 21. DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022(%)

FIGURE 22. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR MONITORING, BY COUNTRY 2022 AND 2032(%)

FIGURE 23. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR DIAGNOSTIC, BY COUNTRY 2022 AND 2032(%)

FIGURE 24. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR PROGNOSTIC, BY COUNTRY 2022 AND 2032(%)

FIGURE 25. DIGITAL BIOMARKERS MARKET, BY END USER, 2022(%)

FIGURE 26. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 27. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR HEALTHCARE CONSUMERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 28. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 29. DIGITAL BIOMARKERS MARKET BY REGION, 2022(%)

FIGURE 30. U.S. DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)

FIGURE 31. CANADA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)

FIGURE 32. MEXICO DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)

FIGURE 33. GERMANY DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)

FIGURE 34. FRANCE DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)

FIGURE 35. UK DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)

FIGURE 36. ITALY DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)

FIGURE 37. SPAIN DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)

FIGURE 38. REST OF EUROPE DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)

FIGURE 39. JAPAN DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)

FIGURE 40. CHINA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)

FIGURE 41. INDIA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)

FIGURE 42. AUSTRALIA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)

FIGURE 43. SOUTH KOREA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)

FIGURE 44. REST OF ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)

FIGURE 45. BRAZIL DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)

FIGURE 46. SOUTH AFRICA, DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)

FIGURE 47. SAUDI ARABIA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)

FIGURE 48. REST OF LAMEA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)

FIGURE 49. TOP WINNING STRATEGIES, BY YEAR

FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 52. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 53. COMPETITIVE DASHBOARD

FIGURE 54. COMPETITIVE HEATMAP: DIGITAL BIOMARKERS MARKET

FIGURE 55. TOP PLAYER POSITIONING, 2022

FIGURE 56. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 57. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 58. AMGEN INC.: REVENUE SHARE BY SEGMENT, 2022 (%